Literature DB >> 21153465

[Manifestation of multiple sclerosis under treatment with infliximab for intermediate uveitis].

M Sczesny-Kaiser1, M Veit, C Heinz, A Heiligenhaus, M Tegenthoff, P Schwenkreis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21153465     DOI： 10.1007/s00115-010-3191-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  5 in total

1.  Interferon as a treatment for uveitis associated with multiple sclerosis.

Authors:  M D Becker; A Heiligenhaus; T Hudde; B Storch-Hagenlocher; B Wildemann; T Barisani-Asenbauer; C Thimm; N Stübiger; M Trieschmann; C Fiehn
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

2.  TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

Authors: 
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

3.  Increased prevalence of autoimmunity in patients with white spot syndromes and their family members.

Authors:  Robert B Pearlman; Pamela R Golchet; Marni G Feldmann; Lawrence A Yannuzzi; Michael J Cooney; Jennifer E Thorne; James C Folk; Edwin H Ryan; Anita Agarwal; Kathleen C Barnes; Kevin G Becker; Lee M Jampol
Journal:  Arch Ophthalmol       Date:  2009-07

Review 4.  Autoimmune diseases induced by biological agents: a double-edged sword?

Authors:  Manuel Ramos-Casals; Candido Diaz-Lagares; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Autoimmun Rev       Date:  2009-10-23       Impact factor: 9.754

5.  Multiple sclerosis associated with uveitis in two large clinic-based series.

Authors:  V Biousse; C Trichet; E Bloch-Michel; E Roullet
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910
  5 in total
  1 in total

1.  Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.

Authors:  Denize Atan; Jarka Heissigerova; Lucia Kuffová; Aideen Hogan; Dara J Kilmartin; John V Forrester; Jeff L Bidwell; Andrew D Dick; Amanda J Churchill
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.